Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedNov 01, 2025
DataAggregated Company Financials
Companies1366
  • 7D-0.7%
  • 3M11.1%
  • 1Y-2.6%
  • YTD4.0%

Over the last 7 days, the Healthcare industry has remained flat, although notably Eli Lilly gained 4.5%. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to grow by 16% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 01 Nov 2025US$5.9tUS$3.1tUS$134.3b26.3x44.3x1.9x
Mon, 29 Sep 2025US$5.7tUS$3.1tUS$137.6b23.6x41.1x1.8x
Wed, 27 Aug 2025US$5.7tUS$3.1tUS$137.2b23.5x41.2x1.8x
Fri, 25 Jul 2025US$5.6tUS$3.0tUS$129.1b25.1x43.4x1.8x
Sun, 22 Jun 2025US$5.5tUS$3.0tUS$127.4b23.7x42.8x1.8x
Tue, 20 May 2025US$5.4tUS$3.0tUS$126.1b24x42.9x1.8x
Thu, 17 Apr 2025US$5.4tUS$2.6tUS$90.0b24.8x59.5x2x
Sat, 15 Mar 2025US$5.6tUS$2.6tUS$74.8b26.6x74.8x2.1x
Mon, 10 Feb 2025US$5.9tUS$2.6tUS$89.8b26.5x65.5x2.2x
Wed, 08 Jan 2025US$5.8tUS$2.9tUS$79.3b27.7x73.4x2x
Fri, 06 Dec 2024US$6.2tUS$2.9tUS$77.4b28.7x79.5x2.1x
Sun, 03 Nov 2024US$6.2tUS$2.9tUS$71.3b28.4x86.4x2.1x
Tue, 01 Oct 2024US$6.2tUS$2.9tUS$70.6b30.3x87.9x2.1x
Thu, 29 Aug 2024US$6.3tUS$2.8tUS$54.0b31.6x116.3x2.2x
Sat, 27 Jul 2024US$6.3tUS$2.8tUS$61.0b31.6x104x2.2x
Mon, 24 Jun 2024US$6.2tUS$2.8tUS$62.5b30x99.2x2.2x
Wed, 22 May 2024US$6.2tUS$2.8tUS$64.2b30.7x96.7x2.2x
Fri, 19 Apr 2024US$5.9tUS$2.8tUS$84.4b30x70.2x2.1x
Sun, 17 Mar 2024US$6.2tUS$2.8tUS$84.5b31.5x73.7x2.2x
Tue, 13 Feb 2024US$6.2tUS$2.8tUS$76.4b32x81.2x2.2x
Thu, 11 Jan 2024US$6.4tUS$2.8tUS$90.1b32.3x70.9x2.3x
Sat, 09 Dec 2023US$6.0tUS$2.8tUS$91.4b29.4x65.1x2.1x
Mon, 06 Nov 2023US$5.7tUS$2.8tUS$88.4b26.7x65x2x
Wed, 04 Oct 2023US$5.8tUS$2.8tUS$98.2b26.5x59.2x2.1x
Fri, 01 Sep 2023US$6.1tUS$2.8tUS$98.8b27.7x61.6x2.2x
Sun, 30 Jul 2023US$6.1tUS$2.8tUS$115.6b28x52.5x2.2x
Tue, 27 Jun 2023US$6.0tUS$2.7tUS$109.8b26.6x54.5x2.2x
Thu, 25 May 2023US$5.9tUS$2.7tUS$110.9b24x53x2.2x
Sat, 22 Apr 2023US$6.0tUS$2.5tUS$117.6b24.9x51x2.4x
Mon, 20 Mar 2023US$5.6tUS$2.5tUS$123.9b23.2x45.3x2.3x
Wed, 15 Feb 2023US$6.0tUS$2.5tUS$130.0b24x45.8x2.4x
Fri, 13 Jan 2023US$6.0tUS$2.5tUS$135.2b23.3x44.6x2.5x
Sun, 11 Dec 2022US$6.1tUS$2.4tUS$133.7b23.6x45.4x2.5x
Tue, 08 Nov 2022US$5.8tUS$2.4tUS$138.1b22.7x42x2.4x
Price to Earnings Ratio

42x


Total Market Cap: US$5.8tTotal Earnings: US$138.1bTotal Revenue: US$2.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 64.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 44.3x which is lower than its 3-year average PE of 64.9x.
  • The 3-year average PS ratio of 2.1x is higher than the industry's current PS ratio of 1.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 8.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market0.46%
Healthcare-0.75%
Biotech3.08%
Pharma1.81%
Life Sciences-2.23%
Healthtech-2.46%
Medical Equipment-2.99%
Healthcare Services-5.82%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 61.8x.
    • Analysts are expecting annual earnings growth of 17.0%, which is higher than its past year's earnings decline of 9.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 24% over the next 5 years.
  • However this is lower than its past earnings growth rate of 61% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$862.864.5%
+US$31.6b		5.4%PE42x
REGN Regeneron PharmaceuticalsUS$651.8012.8%
+US$7.1b		-22.7%PE14.6x
CAH Cardinal HealthUS$190.7717.8%
+US$6.9b		64.3%PE28.4x
INSM InsmedUS$189.6018.8%
+US$6.7b		177.5%PS90.5x
BMY Bristol-Myers SquibbUS$46.075.1%
+US$4.6b		-15.2%PE15.5x

Latest News

AMGN
US$298.43
Amgen
7D
2.3%
1Y
-6.5%
ABBV
US$218.04
AbbVie
7D
-4.4%
1Y
7.1%
BMY
US$46.07
Bristol-Myers Squibb
7D
5.1%
1Y
-15.2%
SYK
US$356.24
Stryker
7D
-6.7%
1Y
-3.0%
LLY
US$862.86
Eli Lilly
7D
4.5%
1Y
5.4%
CI
US$244.41
Cigna Group
7D
-19.0%
1Y
-22.8%
ILMN
US$123.54
Illumina
7D
23.4%
1Y
-17.5%
INSM
US$189.60
Insmed
7D
18.8%
1Y
177.5%
DXCM
US$58.22
DexCom
7D
-17.2%
1Y
-17.2%
EW
US$82.45
Edwards Lifesciences
7D
8.3%
1Y
22.1%
ABT
US$123.62
Abbott Laboratories
7D
-2.5%
1Y
4.2%

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.
CAH
US$190.77
Cardinal Health
7D
17.8%
1Y
64.3%

CAH: Core Pharmaceutical Trends And Automation Will Shape Upcoming Earnings Performance

Cardinal Health's analyst price target has increased from $180 to $216 per share. This reflects stronger confidence in the company's core pharmaceutical business and its ability to deliver on long-term earnings targets, according to recent analyst commentary following robust quarterly results.
UNH
US$341.56
UnitedHealth Group
7D
-5.8%
1Y
-39.8%
REGN
US$651.80
Regeneron Pharmaceuticals
7D
12.8%
1Y
-22.7%

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead

Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.
ELV
US$317.20
Elevance Health
7D
-7.3%
1Y
-23.4%
DHR
US$215.38
Danaher
7D
-3.4%
1Y
-13.1%

Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher

Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.